 |
| |
 |
| |
 |
| |
 |
| |
 |
_____________________________________________________________________________________________________________________
© 2005-9 All Rights Reserved. NOD Pharmaceuticals, Inc.
SHANGHAI, Nov. 23 /PRNewswire-Asia/ -- Shanghai Biolaxy announced the Chinese State Food
oral insulin project (Nodlin), an innovative insulin formulation to treat diabetes. This IND approval
Diabetes is a disorder characteristic of high blood glucose and poor metabolism. The complications
of diabetes often result in severe micro- and macro-vascular diseases, loss of vision, kidney failure,
and amputation. Insulin, as an effective diabetic treatment, can slow down diabetic disease
progression. However, insulin is given by multiple daily injections at present, which significantly
hinders its use.
Oral drug administration is a preferred route. However, the gastrointestinal (GI) tract is designed to
digest nutrients like proteins and presents significant challenges for oral insulin including enzyme
degradation and poor absorption. Currently, there is no approved oral insulin product despite
intensive research in this field.
Nodlin is developed with NOD technology, a patented bio-adhesive nano-particle oral delivery
technology, to overcome the barriers of oral insulin.
"IND approval is a significant milestone achievement for Biolaxy,” quoted from William Lee, CEO.
"We have experienced long delay in the approval process due to regulatory uncertainties, but we are
very happy now Biolaxy is back on track in full speed to develop urgently needed drugs for the
patients.”
For more information, please contact:
William Lee, Ph.D., CEO
Phone: +86-21-6194-0758
Email: info@biolaxy.com
Press Contact
Qianyu Zhao, Ph.D., Director of R&D
Phone: +86-21-6194-0858 x807
Email: info@biolaxy.com
Notes for Editors
About Diabetes and Insulin Treatment
Diabetes has reached epidemic stage. It is estimated that there are 30-40 million diabetic patients in
China with 1.2 million new cases each year. Insulin is a key diabetic treatment with worldwide
market value close to $10 billion. Diabetic patients have to endure multiple daily injections for life
and patients often are reluctant to use insulin despite the clinical proven benefits of early insulin
treatment. Currently, insulin treatment in China particularly is under used.
About Biolaxy
Shanghai Biolaxy is a development stage biotech company and emerging leader in innovative delivery
for biopharmaceuticals. Biolaxy was established in 2005 and is a wholly owned subsidiary of NOD
Pharmaceuticals. Biolaxy uses patented platform technology, nano-particle oral delivery or NOD
technology, to develop oral formulations for biopharmaceuticals, including insulin, exenatide,
interferon, human growth hormone and more.
Nodlin is the first candidate developed with NOD technology and is positioned as basal insulin
formulation based on the pre-clinical data. Nodlin possesses unique pharmacokinetic profile and is
highly competitive.
More information can be found at http://www.biolaxy.com .
SOURCE Shanghai Biolaxy
oral insulin project (Nodlin), an innovative insulin formulation to treat diabetes. This IND approval
Diabetes is a disorder characteristic of high blood glucose and poor metabolism. The complications
of diabetes often result in severe micro- and macro-vascular diseases, loss of vision, kidney failure,
and amputation. Insulin, as an effective diabetic treatment, can slow down diabetic disease
progression. However, insulin is given by multiple daily injections at present, which significantly
hinders its use.
Oral drug administration is a preferred route. However, the gastrointestinal (GI) tract is designed to
digest nutrients like proteins and presents significant challenges for oral insulin including enzyme
degradation and poor absorption. Currently, there is no approved oral insulin product despite
intensive research in this field.
Nodlin is developed with NOD technology, a patented bio-adhesive nano-particle oral delivery
technology, to overcome the barriers of oral insulin.
"IND approval is a significant milestone achievement for Biolaxy,” quoted from William Lee, CEO.
"We have experienced long delay in the approval process due to regulatory uncertainties, but we are
very happy now Biolaxy is back on track in full speed to develop urgently needed drugs for the
patients.”
For more information, please contact:
William Lee, Ph.D., CEO
Phone: +86-21-6194-0758
Email: info@biolaxy.com
Press Contact
Qianyu Zhao, Ph.D., Director of R&D
Phone: +86-21-6194-0858 x807
Email: info@biolaxy.com
Notes for Editors
About Diabetes and Insulin Treatment
Diabetes has reached epidemic stage. It is estimated that there are 30-40 million diabetic patients in
China with 1.2 million new cases each year. Insulin is a key diabetic treatment with worldwide
market value close to $10 billion. Diabetic patients have to endure multiple daily injections for life
and patients often are reluctant to use insulin despite the clinical proven benefits of early insulin
treatment. Currently, insulin treatment in China particularly is under used.
About Biolaxy
Shanghai Biolaxy is a development stage biotech company and emerging leader in innovative delivery
for biopharmaceuticals. Biolaxy was established in 2005 and is a wholly owned subsidiary of NOD
Pharmaceuticals. Biolaxy uses patented platform technology, nano-particle oral delivery or NOD
technology, to develop oral formulations for biopharmaceuticals, including insulin, exenatide,
interferon, human growth hormone and more.
Nodlin is the first candidate developed with NOD technology and is positioned as basal insulin
formulation based on the pre-clinical data. Nodlin possesses unique pharmacokinetic profile and is
highly competitive.
More information can be found at http://www.biolaxy.com .
SOURCE Shanghai Biolaxy
Press Release
 |  |  |
| Biolaxy Secures IND Approval for Oral Insulin |
NOD
Pharmaceuticals, Inc.
| | |